$43.68−2.25 (−4.90%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Edgewise Therapeutics (EWTX) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsQuarter ended How we compute thisNot investment advice
5 figures withheld by our checks. Each blank figure names its reason.
13F fund flowQuarter ended Jun 30, 2026*. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 228 filers, Jun 30, 2026
# 13F FUNDS
228
13F VALUE
$4.9B
119.7M shares
Not reported in the company's filings for this period.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | Fox Jonathan C | director | Acquired · Grant / award | 308 | — | ↗ |
| Aug 13, 2026 | Donovan Joanne M. | CMO | Disposed · Open-market sale | 2,919 | $43.41 | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Acquired · Grant / award | 65,000Stock Option (Right to Buy) | — | ↗ |
| Aug 12, 2026 | Derakhshan Behrad | Chief Business Officer | Acquired · Grant / award | 100,000Stock Option (Right to Buy) | — | ↗ |
| Aug 12, 2026 | Nofi Michael | Chief Financial Officer | Acquired · Grant / award | 48,750Stock Option (Right to Buy) | — | ↗ |
| Aug 12, 2026 | Donovan Joanne M. | CMO | Acquired · Grant / award | 65,000Stock Option (Right to Buy) | — | ↗ |
| Aug 12, 2026 | MOORE JOHN R | General Counsel | Acquired · Grant / award | 65,000Stock Option (Right to Buy) | — | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Acquired · Option exercise | 5,781 | — | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Acquired · Option exercise | 7,031 | — | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Disposed · Open-market sale | 3,238 | $43.68 | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Disposed · Open-market sale | 2,273 | $43.68 | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Disposed · Open-market sale | 390 | $44.46 | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Disposed · Option exercise | 5,781Restricted Stock Units | — | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Disposed · Option exercise | 7,031Restricted Stock Units | — | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Acquired · Grant / award | 32,500Restricted Stock Units | — | ↗ |
| Aug 12, 2026 | Russell Alan J | Chief Scientific Officer | Acquired · Grant / award | 65,000Stock Option (Right to Buy) | — | ↗ |
| Aug 12, 2026 | Derakhshan Behrad | Chief Business Officer | Acquired · Option exercise | 5,781 | — | ↗ |
| Aug 12, 2026 | Derakhshan Behrad | Chief Business Officer | Acquired · Option exercise | 7,500 | — | ↗ |
| Aug 12, 2026 | Derakhshan Behrad | Chief Business Officer | Disposed · Open-market sale | 2,171 | $43.79 | ↗ |
| Aug 12, 2026 | Derakhshan Behrad | Chief Business Officer | Disposed · Open-market sale | 304 | $44.50 | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How many 13F filers hold Edgewise Therapeutics?
Edgewise Therapeutics was held by 228 13F filers as of Jun 30, 2026.
Not investment advice.

